Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells

NCT05183490 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT05183490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05183490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells
Lead sponsor
Columbia University
Phase
Phase 1
Overall status
Recruiting
Start date
May 3, 2022
Completion date
June 30, 2028
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenovirus, bk virus infection, cytomegalovirus infections, epstein-barr virus infections